Cargando…

Impact of IPSS-M implementation in real-life clinical practice

OBJECTIVES: The IPSS-M is a recently published score for risk stratification in myelodysplastic syndromes (MDS), based on clinical and molecular data. We aimed to evaluate its relevance on treatment choice in a real-life setting. METHODS: We retrospectively collected clinical, cytogenetic and molecu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zamanillo, Irene, Poza, Maria, Ayala, Rosa, Rapado, Inmaculada, Martinez-Lopez, Joaquín, Cedena, Maria Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233005/ https://www.ncbi.nlm.nih.gov/pubmed/37274292 http://dx.doi.org/10.3389/fonc.2023.1199023

Ejemplares similares

P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)
por: Zamanillo, Irene, et al.
Publicado: (2023)

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
por: Zamanillo, Irene, et al.
Publicado: (2023)

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2017)

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2018)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
por: Aghdam, Nima, et al.
Publicado: (2020)

Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia
por: Poza, María, et al.
Publicado: (2021)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

P725: BATTLE OF THE GIANTS – COMPARISON OF IPSS-M AND IPSS-R IN PATIENTS WITH MISSING MOLECULAR DATA EXCEPT TP53 MUTATION STATUS FROM THE DÜSSELDORF MDS REGISTRY
por: Schulz, Felicitas, et al.
Publicado: (2023)

Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients
por: Ayala, Rosa, et al.
Publicado: (2011)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

Effect of Depth of Electroacupuncture on the IPSS of Patients with Benign Prostatic Hyperplasia
por: Yuan, Hongwei, et al.
Publicado: (2019)

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
por: Benites, Bruno Deltreggia, et al.
Publicado: (2013)

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
por: Huber, Sandra, et al.
Publicado: (2023)

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma
por: Martinez-Lopez, Joaquin, et al.
Publicado: (2021)

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse
por: Onecha, Esther, et al.
Publicado: (2020)

MPL S505C enhances driver mutations at W515 in essential thrombocythemia
por: Varghese, Leila N., et al.
Publicado: (2021)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
por: Chien, Kelly, et al.
Publicado: (2023)

Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

P840: ASSESSMENT OF CONVENTIONAL TRANSLOCATIONS AND IG REARRANGEMENTS IN THE DIAGNOSIS OF MULTIPLE MYELOMA PATIENTS USING A TARGETED CAPTURE-HYBRIDIZATION RNA SEQUENCING PANEL.
por: Buenache Cuenda, Natalia, et al.
Publicado: (2023)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
por: Onecha, Esther, et al.
Publicado: (2019)

Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
por: Jiménez-Ubieto, Ana, et al.
Publicado: (2023)

Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
por: Jiménez-Ubieto, Ana, et al.
Publicado: (2023)

Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms
por: Cortés, Alicia Arenas, et al.
Publicado: (2019)

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
por: Rodríguez-García, Alba, et al.
Publicado: (2019)

Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome
por: Suh, Koung Jin, et al.
Publicado: (2016)

Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome
por: Ma, Jiale, et al.
Publicado: (2023)

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
por: Papageorgiou, Sotirios G., et al.
Publicado: (2020)

PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.
por: Sánchez-Redondo, Noemí Álvarez, et al.
Publicado: (2023)

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype
por: González-Pérez, Ruperto, et al.
Publicado: (2022)

Specific Quality of Life Assessment by the NutriQoL® Questionnaire Among Patients Receiving Home Enteral Nutrition
por: Zamanillo Campos, Rocío, et al.
Publicado: (2020)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
por: Antonioli, Elisabetta, et al.
Publicado: (2023)

MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2019)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score
por: Silzle, Tobias, et al.
Publicado: (2023)

P1284: LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING PLUS PET-TC MONITORING IN REAL-LIFE FOLLICULAR LYMPHOMA PATIENTS
por: Jiménez-Ubieto, A., et al.
Publicado: (2022)

Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
por: Lopez-Muñoz, N., et al.
Publicado: (2023)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vhluq9mhb7hpuf5fptnt0tj0gr